Morgan Petronelli

In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.

The FDA has approved halobetasol propionate foam, 0.05% (Lexette; Mayne Pharma), a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.

This week’s edition of The Mainstream Patient features stories about albinism, salt water for acne, curl gatekeeping, dry scalp, exercising with psoriatic arthritis, plus more.

Although JAK inhibitors have shown efficacy in treating challenging conditions, federal regulators continue their safety reviews.

Click here to find out what products are trending for the month of September.

Ginette A. Okoye, MD, FAAD, provides several clinical pearls to help physicians find the best therapy for their individual hidradenitis suppurativa patients in her presentation at the Skin of Color Update 2021.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of September.

A review article investigated the psychological effects acne has on adolescent patients.

ICYMI, some of this week’s featured content includes a new podcast episode, and articles about a new black box warning for certain JAK inhibitors, guselkumab vs secukinumab, updates in lasers and light devices, plus more.

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

This week’s edition of The Mainstream Patient features stories about albinism, salt water for acne, curl gatekeeping, dry scalp, exercising with psoriatic arthritis, plus more.

Jennifer Powers, MD, associate professor of dermatology at the University of Iowa, talks her recent research investigating how diet and supplements affect patients with mild psoriasis.

In this video interview, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and why physicians should educate their patients about this type of inflammation.

This week’s edition of The Mainstream Patient features stories about psoriasis and its effect on one's love life, dissolving lip filler, scalp psoriasis, how to safely remove Halloween makeup, plus more.

ICYMI, some of this week’s featured content includes a new podcast episode, video interviews about FDA delays and sunscreen recalls, articles on topline study results for alopecia areata and utilizing the psoriasis toolbox, plus more.

This week’s edition of The Mainstream Patient features stories about psoriasis, pityriasis rosea, microcurrent facials, preventative Botox, plus more.

In this episode, Jennifer Powers, MD, board certified dermatologist and associate professor of dermatology at the University of Iowa, discusses her recent research exploring how diet and supplements affect patients with mild psoriasis.

In this exclusive video interview, David Prokupek, CEO, Ideal Image, sits down with Dermatology Times to discuss the company's new affiliate program aimed at expanding its national point of care network.

Ideal Image has announced the launch of its new affiliate program to help expand its national point of care network.

ICYMI, some of this week’s featured content includes video interviews about ellacor for wrinkles and diversity and wellness in dermatology. Plus, stories on new FDA approvals, advances in the AD pipeline, our top hair loss articles, and more.

In light of National Hair Loss Awareness month, we’ve aggregated our top 10 hair loss articles of 2021 so far.

Vector-borne infectious diseases are spreading and skin cancer is rising because of climate change.

Roy Geronemus, MD, clinical professor of dermatology at New York University Medical Center & Dermatology Times editorial advisory board member, discusses the recent FDA clearance of ellacor Micro-Coring Technology for treatment of moderate to severe wrinkles in the mid to lower face.

The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.

This week’s edition of The Mainstream Patient features stories about gua sha facial massages, kojic acid for hyperpigmentation, fragrance in skin care, plus more.

ICYMI, some of this week’s featured content includes a new podcast episode, video interviews about FDA delays and sunscreen recalls, articles on topline study results for alopecia areata and utilizing the psoriasis toolbox, plus more.

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Ritlecitinib, an investigational covalent kinase inhibitor, achieved its primary endpoint and demonstrated statistically significant efficacy compared to placebo in treating alopecia areata.

In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).